Beginner
- Dose
- 0,25 mg por dia Original in PT-BR
- Frequency
- Uma vez ao dia Original in PT-BR
- Duration
- 24 semanas Original in PT-BR
- Notes
- Dose principal dos estudos de fase 2 e fase 3 citados pelo site. Original in PT-BR
KNOWLEDGE · COMPOUNDS
Tesofensine
Also known as: Tesofensina
MetabolicClinical trials
Overview
Written by EagleThis description was written by Eagle in each of the three languages. It is not imported text and carries no translation warning. What it says comes from the compound’s own composition, its pharmacological class and what the library records — no efficacy claim, and no Eagle recommendation of use.
A página registra comprimido oral, meia-vida de cerca de 9 dias e pesquisa de obesidade; não é uma recomendação de uso.
Tesofensine is catalogued under Metabolic. 0 Eagle articles in this library reference this compound.
- Category
- Metabolic
- Research stage
- Clinical trials — Ensaios clínicos; não aprovada nos EUA Original in PT-BR
- Eagle articles on this compound
- 0 Eagle articles
Mechanism
O site descreve tesofensina como bloqueadora da recaptação de dopamina, norepinefrina e serotonina. Original in PT-BR
Chemical information
- CAS
- Not recorded in the source.
- Molecular formula
- Not recorded in the source.
- Molecular weight
- Not recorded in the source.
- Sequence
- Not recorded in the source.
- Amino acids
- Not recorded in the source.
- Solubility
- Not recorded in the source.
- Stability
- Not recorded in the source.
- Half-life
- Cerca de 9 dias Original in PT-BR
- Bioavailability
- Not recorded in the source.
- Onset
- Not recorded in the source.
- Routes
- Oral
Research references
No individual dosing recommendation is given. Values are as recorded in the source, with species and route stated where known.
Astrup et al. (2008), estudo de fase 2 citado pelo site; 0,25 mg e 0,5 mg por 24 semanas. Original in PT-BR
Year: 2008Species: Not recorded as a structured field in the source.Route: Not recorded as a structured field in the source.Duration: Not recorded as a structured field in the source.Purpose: Not recorded as a structured field in the source.
Safety
No safety information recorded in the source.
Lab tests named in the source
- Pressão arterial e frequência cardíaca de repouso
- Perfil lipídico
- Painel metabólico abrangente (CMP)
The source names the tests and nothing else: no reference values and no thresholds. None were added here. Interpreting a result is a clinical act and is not offered on this page.
Reported protocols
Recorded in the imported source as community protocols. They are NOT Eagle protocols, were not reviewed by Eagle, and are not a dosing recommendation, a prescription or clinical guidance. Values appear exactly as recorded, in the language they were written in.
Intermediate
- Dose
- 0,5 mg por dia Original in PT-BR
- Frequency
- Uma vez ao dia Original in PT-BR
- Duration
- 24 semanas Original in PT-BR
- Notes
- O site relata cerca de 9–10% de perda de peso subtraída do placebo nesse contexto. Original in PT-BR
Advanced
- Dose
- 1,0 mg por dia Original in PT-BR
- Frequency
- Uma vez ao dia Original in PT-BR
- Duration
- 24 semanas Original in PT-BR
- Notes
- Fase 2; o site registra mais problemas de pressão arterial e abandonos, e informa que a dose saiu dos estudos posteriores. Original in PT-BR
Vial sizes: Comprimidos de 0,25 mg · Comprimidos de 0,5 mg — Peptide Calculator
Interactions
No relations recorded in the source.
Related
No Eagle article in this library references this compound yet.